Cargando…

Patient Satisfaction with CIMZIA(®) (Certolizumab Pegol) AutoClicks(®) in the UK

INTRODUCTION: The CIMZIA(®) AutoClicks(®) pre-filled pen (CZP PFP) was developed to overcome barriers to self-injection, by improving self-injection confidence, reducing fear associated with needle use, and supporting patients with impaired dexterity. The purpose of this research was to gather feedb...

Descripción completa

Detalles Bibliográficos
Autores principales: Bailey, Kathryn, Mountian, Irina, Bruggraber, Richard, Sunderland, Kerri, Tilt, Nicola, Szegvari, Boglarka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7140744/
https://www.ncbi.nlm.nih.gov/pubmed/32124272
http://dx.doi.org/10.1007/s12325-020-01257-6
_version_ 1783519060737130496
author Bailey, Kathryn
Mountian, Irina
Bruggraber, Richard
Sunderland, Kerri
Tilt, Nicola
Szegvari, Boglarka
author_facet Bailey, Kathryn
Mountian, Irina
Bruggraber, Richard
Sunderland, Kerri
Tilt, Nicola
Szegvari, Boglarka
author_sort Bailey, Kathryn
collection PubMed
description INTRODUCTION: The CIMZIA(®) AutoClicks(®) pre-filled pen (CZP PFP) was developed to overcome barriers to self-injection, by improving self-injection confidence, reducing fear associated with needle use, and supporting patients with impaired dexterity. The purpose of this research was to gather feedback on injection experience and the usefulness of training materials. METHODS: Eligible patients with rheumatoid arthritis (RA), axial spondyloarthritis (axSpA) or psoriatic arthritis (PsA) were at least 18 years of age and initiated onto the CZP PFP. Routine self-injection training and support were provided by trained specialist nurses. Patient experience (pain and skin reactions, confidence, satisfaction, and ease of use) was evaluated at visits 1–3 using an amended version of the self-injection assessment questionnaire (SIAQ) v2.0. Nurse and patient feedback on the training materials, and nurse opinions on patient self-injection after self-injection at visit 1, were also collected. RESULTS: Of 355 patients invited to participate, 196 provided informed consent and 79 participated in all three visits. Patients generally found the CZP PFP easy to use, and self-confidence and satisfaction were high. From visit 1 to visit 3, there was a numerical trend towards improvement in all three aspects of patient experience, most notably in both confidence and satisfaction. After self-injection at visit 1, confidence around safe patient self-injection was higher among nurses than among patients. Meanwhile, “pain and skin reactions” remained low at all visits. Patients thought the training materials contained sufficient information and were easy to understand and useful. CONCLUSION: After training, patients generally found the device easy to use and showed high confidence and satisfaction with self-injection. Some patients may have been competent (based on nurse opinion), but initially lacked self-confidence. Increasing self-injection experience, together with patient training and continued support, may have facilitated high patient confidence and satisfaction, thereby potentially overcoming some of the barriers to self-injection. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s12325-020-01257-6) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-7140744
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-71407442020-04-14 Patient Satisfaction with CIMZIA(®) (Certolizumab Pegol) AutoClicks(®) in the UK Bailey, Kathryn Mountian, Irina Bruggraber, Richard Sunderland, Kerri Tilt, Nicola Szegvari, Boglarka Adv Ther Original Research INTRODUCTION: The CIMZIA(®) AutoClicks(®) pre-filled pen (CZP PFP) was developed to overcome barriers to self-injection, by improving self-injection confidence, reducing fear associated with needle use, and supporting patients with impaired dexterity. The purpose of this research was to gather feedback on injection experience and the usefulness of training materials. METHODS: Eligible patients with rheumatoid arthritis (RA), axial spondyloarthritis (axSpA) or psoriatic arthritis (PsA) were at least 18 years of age and initiated onto the CZP PFP. Routine self-injection training and support were provided by trained specialist nurses. Patient experience (pain and skin reactions, confidence, satisfaction, and ease of use) was evaluated at visits 1–3 using an amended version of the self-injection assessment questionnaire (SIAQ) v2.0. Nurse and patient feedback on the training materials, and nurse opinions on patient self-injection after self-injection at visit 1, were also collected. RESULTS: Of 355 patients invited to participate, 196 provided informed consent and 79 participated in all three visits. Patients generally found the CZP PFP easy to use, and self-confidence and satisfaction were high. From visit 1 to visit 3, there was a numerical trend towards improvement in all three aspects of patient experience, most notably in both confidence and satisfaction. After self-injection at visit 1, confidence around safe patient self-injection was higher among nurses than among patients. Meanwhile, “pain and skin reactions” remained low at all visits. Patients thought the training materials contained sufficient information and were easy to understand and useful. CONCLUSION: After training, patients generally found the device easy to use and showed high confidence and satisfaction with self-injection. Some patients may have been competent (based on nurse opinion), but initially lacked self-confidence. Increasing self-injection experience, together with patient training and continued support, may have facilitated high patient confidence and satisfaction, thereby potentially overcoming some of the barriers to self-injection. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s12325-020-01257-6) contains supplementary material, which is available to authorized users. Springer Healthcare 2020-03-02 2020 /pmc/articles/PMC7140744/ /pubmed/32124272 http://dx.doi.org/10.1007/s12325-020-01257-6 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research
Bailey, Kathryn
Mountian, Irina
Bruggraber, Richard
Sunderland, Kerri
Tilt, Nicola
Szegvari, Boglarka
Patient Satisfaction with CIMZIA(®) (Certolizumab Pegol) AutoClicks(®) in the UK
title Patient Satisfaction with CIMZIA(®) (Certolizumab Pegol) AutoClicks(®) in the UK
title_full Patient Satisfaction with CIMZIA(®) (Certolizumab Pegol) AutoClicks(®) in the UK
title_fullStr Patient Satisfaction with CIMZIA(®) (Certolizumab Pegol) AutoClicks(®) in the UK
title_full_unstemmed Patient Satisfaction with CIMZIA(®) (Certolizumab Pegol) AutoClicks(®) in the UK
title_short Patient Satisfaction with CIMZIA(®) (Certolizumab Pegol) AutoClicks(®) in the UK
title_sort patient satisfaction with cimzia(®) (certolizumab pegol) autoclicks(®) in the uk
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7140744/
https://www.ncbi.nlm.nih.gov/pubmed/32124272
http://dx.doi.org/10.1007/s12325-020-01257-6
work_keys_str_mv AT baileykathryn patientsatisfactionwithcimziacertolizumabpegolautoclicksintheuk
AT mountianirina patientsatisfactionwithcimziacertolizumabpegolautoclicksintheuk
AT bruggraberrichard patientsatisfactionwithcimziacertolizumabpegolautoclicksintheuk
AT sunderlandkerri patientsatisfactionwithcimziacertolizumabpegolautoclicksintheuk
AT tiltnicola patientsatisfactionwithcimziacertolizumabpegolautoclicksintheuk
AT szegvariboglarka patientsatisfactionwithcimziacertolizumabpegolautoclicksintheuk